Citation Impact
Citing Papers
Prospective identification of tumorigenic breast cancer cells
2003 Standout
Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
2008
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
2010 Standout
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
2003 Standout
Tumour-cell invasion and migration: diversity and escape mechanisms
2003 Standout
The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
2002
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
2009
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
2000
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
2004
Untangling the ErbB signalling network
2001 Standout
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
1999
Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe
2001
Molecular Markers for Predicting Response to Tamoxifen in Breast Cancer Patients
2000
Letrozole in the extended adjuvant setting: MA.17
2007
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
2001
The Predictive Value of HER2 in Breast Cancer
2001
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Overcoming Endocrine Therapy Resistance by Signal Transduction Inhibition
2004
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Trastuzumab Plus Tamoxifen: Anti-Proliferative and Molecular Interactions in Breast Carcinoma
2004
HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.
2001
HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer
2004
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Catalytic Asymmetric Three‐Component Synthesis of Homoallylic Amines
2013 StandoutNobel
Phyto-oestrogens: where are we now?
1998
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer
2000
Successful use of letrozole in male breast cancer: A case report and review of hormonal therapy for male breast cancer
2005
The role of extracellular matrix in small-cell lung cancer
2001
β-Arrestin Is Crucial for Ubiquitination and Down-regulation of the Insulin-like Growth Factor-1 Receptor by Acting as Adaptor for the MDM2 E3 Ligase
2005 StandoutNobel
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
Personalized treatment of early-stage breast cancer: Present concepts and future directions
2010
Breast cancer
2016 Standout
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Chemotherapy for small cell lung cancer
2003
Aromatase Inhibitors in Breast Cancer
2003
The Role of the Epidermal Growth Factor Receptor Family in Mammary Tumorigenesis and Metastasis
1999
Oncogenic kinase signalling
2001 StandoutNature
Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer
2006
Imaging in the era of molecular oncology
2008 StandoutNature
Endometriosis
2009 Standout
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
1998
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Efficacy of Anastrozole in Male Breast Cancer
2002
Aromatase inhibitors: the next generation of therapeutics for endometriosis?
2006
Osteoporosis: now and the future
2011 Standout
Carcinoma of the Male Breast
1992
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Assessing responses to cancer therapy using molecular imaging
2006
Historical perspective on hormonal therapy of advanced breast cancer
2002
Epithelial–mesenchymal transitions in tumour progression
2002 Standout
Tamoxifen in the Treatment of Breast Cancer
1988
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
2004 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
1998 Standout
Male breast cancer
2006 Standout
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Chemotherapy as treatment of primary and recurrent small cell lung cancer
2001
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy
2003
Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis
2011 Standout
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Microtubules as a target for anticancer drugs
2004 Standout
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer
2003
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
β-Arrestin and Mdm2 Mediate IGF-1 Receptor-stimulated ERK Activation and Cell Cycle Progression
2007 StandoutNobel
Production and Actions of Estrogens
2002 Standout
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification
2002 Standout
Economic Evaluation of Gemcitabine Alone and in Combination with Cisplatin in the Treatment of Nonsmall Cell Lung Cancer
2002
Clinical imaging of cancer metastasis
2000
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Preservation of Fertility in Patients with Cancer
2009 Standout
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
2005
Molecular and Cellular Aspects of the Insulin-Like Growth Factor I Receptor
1995
Advances in Malignant Mesothelioma
2005 Standout
Anemia of Chronic Disease
2005 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy
1998
The pharmacology and clinical uses of tamoxifen
1984
Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II Study
1999
Medroxyprogesterone Acetate Elevation of Nm23-H1 Metastasis Suppressor Expression in Hormone Receptor–Negative Breast Cancer
2005
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
2009 Standout
Aromatase Inhibitors in the Treatment of Breast Cancer
2005
Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast.
2002
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth
2000
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
1992 Standout
2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
2001
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
1999
Structural Investigations into the Stereochemistry and Activity of a Phenylalanine-2,3-aminomutase from Taxus chinensis
2014 StandoutNobel
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
2002 StandoutScience
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
1997
A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling
2005 StandoutScience
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
A review of the management of the male breast carcinoma based on an analysis of 420 treated cases
1996
Works of I E Smith being referenced
Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
1999
Role of Herceptin<sup>®</sup> in Primary Breast Cancer: Views from North America and Europe
2001
Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
1997
MMM (Mitomycin/Mitoxantrone/Methotrexate): An Effective New Regimen in the Treatment of Metastatic Breast Cancer
1993
Somatomedin-C/insulin-like growth factor-I is a mitogen for human small cell lung cancer
1988
Activity of docetaxel (Taxotere) in small cell lung cancer
1994
Results of an independent oncology review board of pivotal clinical trials of gemcitabine in non-small cell lung cancer
1999
The effect of a low-fat diet on hormone levels in healthy pre- and postmenopausal women: relevance for breast cancer
1992
High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer
1987
Tumor Ki67 Proliferation Index within 4 Weeks of Initiating Neoadjuvant Endocrine Therapy for Early Identification of Non-Responders.
2009
Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells
1991
S25 Update of the HERA trial and the role of 1 year Trastuzumab as adjuvant therapy for breast cancer
2009
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
1998
Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized31P measurements of response to treatment
1998
LOW-DOSE AMINOGLUTETHIMIDE IN TREATMENT OF ADVANCED BREAST CANCER
1984
S41 Targeting HER2 in the adjuvant setting: Dealing with new standards and open questions
2009
Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.
1982
75 Good symptom relief with palliative MVP (mitomycin c, vinblastine, cisplatin) chemotherapy in malignant mesothelioma
1997
Role of aminoglutethimide in male breast cancer
1987